Invitrocue: Your partner for personalized oncology.
Invitrocue is a world-class innovative life sciences company that specialises in developing ground-breaking 3D cell-based models such as Patient-Derived Organoids from all solid cancers.
By utilizing Onco-PDO test, we perform in vitro drug screenings on PDOs to provide the oncologists with the information to better direct patient therapy and personalized patient treatment.
By enabling assessments of the best ways for drugs to be developed, we impart to the industry valuable knowledge in creating better, faster and more affordable disease treatments, working towards the company’s goal of creating a healthier society by providing patients with the best possible care.
Our business involves developing and commercialising a series of technologies derived from Singapore’s Agency for Science, Technology and Research (A*STAR)
Invitrocue was first founded in 2012 to commercialize proprietary 3D cell culture technology developed at A*STAR’s Institute of Bioengineering and Nanotechnology in Singapore, Massachusetts Institute of Technology Cambridge, and the Genome Institute of Singapore. These technologies and know how have since been successfully developed into commercial services such as in vitro Human Liver models for drug toxicology testing, in vitro Human NASH (Fatty Liver) model, in vitro Human Liver infection models, in vitro Human Respiratory models, in vitro Human Oncology Organoids and in vivo Humanized Immune Organoid. These technologies are a key advancement in supporting the treatment in a range of cancers with leading global Cancer centers and leading pharmaceutical companies in their drug development programs. Invitrocue is headquartered in Singapore, with operations in Germany, Spain, Brazil, Australia, China and Hong Kong.